Current Report Filing (8-k)
April 08 2020 - 6:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
April 7, 2020
CORMEDIX
INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-34673
|
|
20-5894890
|
(State of other jurisdiction of
incorporation or organization)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
400 Connell Drive, Suite 5000
Berkeley Heights, NJ
|
|
07922
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (908) 517-9500
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2, below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Exchange
Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common stock, $0.001 par value
|
|
CRMD
|
|
NYSE American LLC
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On April 7, 2020, CorMedix Inc. (the “Company”) issued
a letter to its shareholders regarding the impact of the COVID-19 global pandemic on the Company’s operations and objectives,
including on securing regulatory approval of Neutrolin®. A copy of the letter to shareholders is furnished as Exhibit 99.1
to this report.
|
Item 9.01.
|
Financial Statements and Exhibits
|
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
CORMEDIX INC.
|
|
|
|
Date: April 7, 2020
|
By:
|
/s/ Khoso Baluch
|
|
Name:
|
Khoso Baluch
|
|
Title:
|
Chief Executive Officer
|
CorMedix (AMEX:CRMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
CorMedix (AMEX:CRMD)
Historical Stock Chart
From Apr 2023 to Apr 2024